Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

被引：10

作者：

Jang, Seong Bok ^{[1
]}

Kim, Kyeong Bae ^{[2
]}

Sim, Sujin ^{[1
]}

Cho, Byoung Chul ^{[3
]}

Ahn, Myung-Ju ^{[4
]}

Han, Ji-Youn ^{[5
]}

Kim, Sang -We ^{[6
]}

Lee, Ki Hyeong ^{[7
]}

Cho, Eun Kyung ^{[8
]}

Haddish-Berhane, Nahor ^{[9
]}

Mehta, Jaydeep ^{[9
]}

Oh, Se-Woong ^{[2
,10
]}

机构：

[1] Yuhan Corp, Clin Dev Dept, Seoul, South Korea

[2] Yuhan Corp, Yuhan R&D Inst, Yongin, South Korea

[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[5] Natl Canc Ctr, Ctr Lung Canc, Res Inst & Hosp, Goyang, South Korea

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Med, Div Med Oncol,Coll Med, Cheongju, South Korea

[8] Gachon Univ, Coll Med, Gil Med Ctr, Incheon, South Korea

[9] Janssen R&D, Spring House, PA USA

[10] Yuhan Corp, Yuhan R&D Inst, 25 Tapsil Ro,35 Beon Gil, Yongin 17084, Gyeonggi Do, South Korea

来源：

JTO CLINICAL AND RESEARCH REPORTS | 2021年 / 2卷 / 10期

关键词：

Non-small cell lung cancer; Tyrosine kinase in-hibitor; Lazertinib; Cardiac toxicity; TYROSINE KINASE INHIBITORS; INTERVAL PROLONGATION; ADVERSE EVENTS; QTC-INTERVAL; OSIMERTINIB; DYSFUNCTION; CARDIOTOXICITY; REPOLARIZATION; MECHANISMS; DRUGS;

D O I：

10.1016/j.jtocrr.2021.100224

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Lazertinib is a potent, irreversible, brain -penetrant, mutant-selective, and wild-type-sparing third -generation EGFR tyrosine kinase inhibitor (TKI), creating a wide therapeutic index. Cardiovascular adverse events (AEs), including QT prolongation, decreased left ventricular ejection fraction (LVEF), and heart failure, have emerged as potential AEs with certain EGFR TKI therapies.Methods: Cardiac safety of lazertinib was evaluated in TKI-tolerant adults with EGFR mutation-positive locally advanced or metastatic NSCLC receiving lazertinib (20-320 mg/d). QT intervals corrected with Fridericia's formula (QTcF) prolongation, time-matched concentration-QTcF relationship, change of LVEF, and cardiac failure-associated AEs were evaluated. The clinical findings were supple-mented by the following three preclinical studies: an in vitro hERG inhibition assay, an ex vivo isolated perfused rabbit heart study, and an in vivo telemetry-instrumented beagle dog study.Results: Preclinical evaluation revealed little to no physio-logical effect on the basis of electrocardiogram, electro-physiological, proarrhythmic, and hemodynamic parameters. Clinical evaluation of 181 patients revealed no clinically relevant QTcF prolongation by centralized elec-trocardiogram in any patient and at any dose level. The predicted magnitude of QTcF value increase at maximum steady-state plasma concentration for the therapeutic dose of lazertinib (240 mg/d) was 2.2 msec (upper bound of the two-sided 90% confidence interval: 3.6 msec). No patient had clinically relevant LVEF decrease (i.e., minimum post -baseline LVEF value of <50% and a maximum decrease in LVEF value from baseline of >10 percentage points). Car-diac failure-associated AE occurred in one patient (grade 2 decreased LVEF) and resolved without any dose modifications.Conclusions: Our first-in-human study, together with pre -clinical data, indicates that lazertinib is not associated with increased cardiac risk.(c) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.

引用

页数：11